NeuraLight appoints Dr. Gil Shklarski as Scientific Co-founder and Board Observer

NeuraLight, a company that digitizes neurological insights using AI, has announced that it has added Gil Shklarski, Ph.D. as Scientific Co-founder and Board Observer. In his new role, Dr. Shklarski will help the company with its next phase of growth as it evolves from Seed to a Series A round.

“Having been an early investor in NeuraLight from the start, I’ve been impressed with the quality of people the company has brought on and the velocity in tech, clinical, and commercial discovery they’ve had in the last year,” said Dr. Shklarski. “I decided to join as an integral part of the team because I truly believe the team and technology have the potential to transform the lives of people with neurological disorders, and I look forward to helping implement this technology in clinical trials at the commercial level.”

Before joining NeuraLight, Dr. Shklarski served as CTO of Flatiron Health, a healthtech company focused on cancer treatment and research, which was acquired by Roche for $1.9 billion. While there, he oversaw software engineering, information security, data insight engineering, and product design functions. Before Flatiron, he built data processing systems for Microsoft, Facebook, and the Israel Defense Forces, both as a developer and a manager.

“Adding Gil to our team is one of those rare inflection points that will change the trajectory of our company for years to come,” added Dr. Micha Breakstone, CEO and Co-founder of NeuraLight. “Gil is not only one of the most brilliant operators we've worked with, but one of the most dedicated and thoughtful ones, and having Gil’s expertise in the digital health space will be invaluable as we drive forward into 2022.”

Dr. Shklarsi has been involved with NeuraLight for more than four years, starting his involvement as an investor and advisor. He has worked with the company’s CTO and Co-Founder, Eddy Ben-Ami in the space of signal processing for 20 years and will help NeuraLight leverage proprietary Computer Vision and Deep Learning technology.

NeuraLight launched from stealth in October 2021 with the announcement of a $5.5 million investment co-led by MSAD.vc, Kli Capital, and Tuesday Capital. Its AI-driven platform integrates digital markets to accelerate and improve drug development, monitoring, and precision care for patients with neurological disorders. Dr. Shklarski currently serves as General Partner at Operator Partners and at NeuraLight and will work closely with management to define the strategic playbook and execute the commercial aspects as the company launches its first clinical trials.